Lumenis announced the launch of its 2026 Accelerate education series, a nationwide peer-to-peer learning initiative designed to help eye care professionals expand procedural services, strengthen clinical confidence, and integrate advanced therapeutic technologies into modern practice settings. The educational series reflects the company’s continued focus on advancing eye care through clinician training, collaboration and practice development support.

This year’s Accelerate program officially kicked off in Orlando, Florida, with additional events scheduled for New York City on May 15-16, Newport Beach, California, on June 5-6, and Chicago on Aug. 28-30. Lumenis said more locations and dates will be announced later this year.

Presented by eye care professionals for eye care professionals, the Accelerate series aims to combine interactive learning with real-world clinical insights. Each event includes facilitated breakout sessions, live demonstrations and peer-led case discussions focused on incorporating in-office procedures, improving patient experience, streamlining workflows and building sustainable specialty care offerings.

“Many eye care professionals are actively looking for ways to diversify revenue, reduce reliance on traditional reimbursement, and meet patient expectations for advanced in-office care,” said Stacey Winter, president of North America for Lumenis. “Accelerate creates a forum where clinicians can learn directly from peers who have successfully integrated advanced technologies into everyday practice.”

The program features presentations and clinical perspectives from experienced practitioners including Celesta Ferreira, OD, and Inna Lazar, OD, who share insights into integrating advanced treatment technologies into routine patient care. Attendees also participate in hands-on training sessions with several of the company’s ophthalmic technologies, including OptiLIFT Dynamic Muscle Stimulation Technology (DMSt), OptiLIGHT intense pulsed light (IPL) therapy and OptiPLUS dual-frequency radiofrequency (RF) technology. OptiLIGHT remains the first and only IPL device approved by the FDA for the management of dry eye disease.

In addition to clinical education, the Accelerate series emphasizes professional networking and collaboration through breakout discussions, hosted meals and evening social events, including a cocktail reception.

Eye care professionals interested in attending upcoming Accelerate events can register through the Lumenis Vision events portal.